Paul Andrew Moore, the Chief Scientific Officer of $ZYME ($ZYME), sold 9,792 shares of the company on 01-06-2025. We received data on the trade from a recent SEC filing. This was a sale of approximately 39.9% of their shares. Following this trade, they now own 14,741 shares of $ZYME stock.
$ZYME Insider Trading Activity
$ZYME insiders have traded $ZYME stock on the open market 11 times in the past 6 months. Of those trades, 6 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $ZYME stock by insiders over the last 6 months:
- JEFFREY T L SMITH (EVP & Chief Medical Officer) sold 11,110 shares.
- PAUL ANDREW MOORE (Chief Scientific Officer) has traded it 2 times. They made 0 purchases and 2 sales, selling 21,200 shares.
- KENNETH GALBRAITH (Chair & CEO) has traded it 2 times. They made 0 purchases and 2 sales, selling 57,291 shares.
- CAPITAL, LLC ECOR1 has traded it 6 times. They made 6 purchases, buying 493,678 shares and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ZYME Hedge Fund Activity
We have seen 65 institutional investors add shares of $ZYME stock to their portfolio, and 73 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BVF INC/IL removed 1,262,065 shares (-21.5%) from their portfolio in Q3 2024
- NEXTECH INVEST LTD. added 1,113,946 shares (+inf%) to their portfolio in Q3 2024
- MORGAN STANLEY added 867,422 shares (+20.5%) to their portfolio in Q3 2024
- DEUTSCHE BANK AG\ removed 829,266 shares (-35.2%) from their portfolio in Q3 2024
- CITADEL ADVISORS LLC removed 578,574 shares (-96.5%) from their portfolio in Q3 2024
- PERCEPTIVE ADVISORS LLC added 512,309 shares (+30.7%) to their portfolio in Q3 2024
- SILVERCREST ASSET MANAGEMENT GROUP LLC removed 511,173 shares (-64.2%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
